Form 4: Biocryst Pharmaceuticals Director Acquires Shares

Biocryst Pharmaceuticals Director Jill C. Milne acquired 1,262 shares of common stock on May 29, 2026, as a substitute for her quarterly board member retainer.

Summary

• Director Jill C. Milne acquired 1,262 shares of Biocryst Pharmaceuticals Inc. common stock on May 29, 2026.
• The acquisition was made in lieu of 100% of her quarterly cash Board Member retainer, valued at $11,250.
• The shares were acquired at a price of $8.91 per share.
• Following this transaction, Ms. Milne beneficially owns 16,644 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine compensation adjustment for a director rather than a significant strategic or financial event.

Positives

• Director's continued investment in the company through share acquisition.
• Alignment of director compensation with equity ownership.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that this Form 4 filing indicates a common practice where board members receive equity in lieu of cash compensation, aligning their interests with shareholders. This is a standard practice in the pharmaceutical and biotechnology sectors.

Stakeholder Impact

• Shareholders: The transaction reinforces the alignment of director interests with those of shareholders by increasing equity ownership.

Key Dates

Keywords

Biocryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Director Compensation, Share Acquisition